Developments in Prostate Cancer Imaging
Pgs. 5 & 8

PCRI’s New Look
Pg. 10

The Mid-Year Update
PCRI’s New April Conference
Pg. 11

Psychological Side Effects of Hormone Therapy
Pg. 12

Bone Health & Osteoporosis
Pg. 15
Dear Insights Reader,

Happy New Year! You have probably noticed that PCRI is starting to look different. We have updated a few things, including our logo and slogan, to better reflect who we are and what we do. In the “program update” section of this issue, I will briefly discuss the significance of these changes.

In light of our Imaging Awareness Matching Gift Campaign, we wanted to highlight a few prostate imaging developments in this issue. Dr. Fabio Almeida, who will be speaking at our new Mid-Year Update Conference (more details later in this issue), will explain how PET imaging works, and discuss what is on the horizon for molecular imaging. Dr. Dan Margolis (also speaking at the Mid-Year Update) will discuss PI-RADS V2, a new numbering system that standardizes use of MRI imaging for prostate cancer. Also in this issue, Richard Wassersug, PhD, will discuss psychological side effects of hormone therapy and how they impact quality of life. Finally, our Senior Educational Facilitator, Jan Manarite, will cover a topic that comes up often on helpline calls: Bone integrity and osteoporosis.

We are excited to bring you these updates and hope that what you read will help you with your continued research about prostate cancer, and answer questions you might have.

-Peter Scholz, Insights Editor
Editorial Staff

Editor: Peter Scholz
Editorial Contributor: Jan Manarite
Review Board:
Duke K. Bahn, M.D.
Stanley A. Brosman, M.D.
Arthur N. Lurvey, M.D.
Mark C. Scholz, M.D.
Michael Steinberg, M.D.

Board of Directors

Chester A Swenson, President, Chairman
Business Consultant/Entrepreneur

Michael Steinberg, M.D., Vice President
Professor and Chair, Department of Radiation Oncology, and
David Geffen School of Medicine,

Harry Hathaway, Esq., Secretary
Fulbright & Jaworski LLP

Mark C. Scholz, M.D., Executive Director/Treasurer & Co-Founder
Director, Prostate Oncology Specialists

Duke K. Bahn, M.D.
Director, Prostate Institute of America

Stanley A. Brosman, M.D.
Pacific Urology Institute, Pacific Clinical Research

Scott Cohen
Chief Executive Officer, 180Fusion

Arthur N. Lurvey, M.D., F.A.C.P., F.A.C.E.
Contractor Medical Director, JE

Jerry Peters
MCG Records

Claudia B. Sangster, Esq.
Director of Philanthropy, Planning CTC, myCFO, Inc.

Jerome Seliger, Ph.D.
Professor of Health Administration, California
State University, Northridge
5  The Latest in Molecular Imaging
   Fabio Almeida, MD, Director, Arizona Molecular Imaging Center

   Dr. Almeida discusses how PET scans can be used to detect small recurrences, and describes the different ways they are used for prostate cancer.

8  PI-RADS V2: New Recommendations for Multi-Parametric MRI
   Daniel Margolis, MD, Associate Professor, University of California Los Angeles

   Dr. Margolis covers new developments with mp-MRI and how they will help to standardize mp-MRI for prostate cancer.

9  Helpline Corner: Trust Your Instincts
   Jan Manarite, Senior Educational Facilitator, PCRI & John Mullineaux, Helpline Facilitator, PCRI

   Jan Manarite and John Mullineaux, from PCRI’s helpline, share an empowering story that emphasizes the importance of the shared decision making process.

10 PCRI Program Update: PCRI’s New Look
    Peter Scholz, Communications Manager, PCRI

    Peter Scholz covers the new look of PCRI and how it relates to our mission and the development of the prostate cancer landscape.

12 The Psychological Side Effects of Hormone Therapy
    Richard Wassersug, Ph.D, Adjunct Professor Department of Urologic Sciences at University of British Columbia

    Dr. Wassersug highlights the side effects of hormone therapy that are often overlooked and the difficulty that they can place on relationships and overall well-being.

16 Bone Health and Prostate Cancer: Understanding Your Risk of Osteoporosis
    Jan Manarite, Senior Educational Facilitator

    Jan Manarite discusses another common side effect of hormone therapy and the different treatments available to combat osteoporosis in men.

18 The 2015 Prostate Cancer Conference
The treatment landscape for prostate cancer has been revolutionized by the arrival of multiple novel treatment approaches and agents over the last few years. After initial treatment with surgery or radiation however, up to 40% of patients will experience PSA relapse. Knowing the location of a cancer recurrence is important since recurrence in or near the pelvic lymph nodes may be amenable to additional curative focal therapy.

The primary difficulty is that standard imaging techniques such as technetium bone scan, CT scans and MRI are usually unable to see tiny recurrent tumors. On the other hand, PET scans that work by exploiting various aspects of cancer metabolism, can often visualize and locate these small tumors. In this article I will review some of the exciting new technology that is becoming available.

Growing Cancer Cells Need to Manufacture New Lipid Cell Membranes

Cell membrane synthesis and the building blocks—acetate and choline—are common structural elements in the cancer cell. Therefore, if these areas of the cancer cell are made radioactive with carbon-11 or fluoride-18 they will “light up” on a body scan.

In the study I presented at the meeting, 373 patients with PSA recurrence were evaluated with C11 Acetate PET scan. We found that the cancer detection rates co-related with the patient’s level of PSA. For example, if the PSA was between 0.2-0.4 we had 50% cancer detection rate. If the PSA was between 0.41 – 1.0 the detection rate was 77%. When the PSA was over 1.1, detection was was 90%.
PSMA (Prostate Specific Membrane Antigen)

Some of the studies presented from other centers were also very interesting. For example, PSMA is a cell surface transmembrane glycoprotein that is over-expressed in prostate cancer cells and would appear to provide a rational target for diagnostic imaging and possible directed therapy. Multiple Gallium (Ga68) labeled PSMA probes (imaging agents) have been topic of study particularly in Germany for the last few years. Researcher from Germany, Dr. Frederick Giesel, presented his work on Gallium-PSMA PET in pre-treatment staging prior to radiation therapy. His study found that in 26 of 56 (46.4%) patients the treatment plan was changed after Gallium-PSMA PET imaging. This study demonstrates the significant impact that PET imaging probes can have on the treatment selection of patients with primary prostate cancer.

An interesting departure from the PET agents discussed in this session was a presentation regarding trofolastat, which is a small molecule PSMA ligand. This agent is labeled with Technetium-99m which is a SPECT radiotracer. This study reviewed the ability of trofolastat to detect prostate cancer in 54 high risk patients within the prostate gland and found correlation for the detection of the primary cancer in 91% of patients. Problematic was that all patients in this study had high risk disease with large prostate cancers and/or extra-prostatic extension (T3 or greater). Yet in 6 of the study patients, the primary prostate cancer was not identified at all! In this setting, one would hope for a near 100% detection rate for the primary cancer.

Amio Acid PET Scans

A synthetic non-metabolized amino acid analog (anti-18F-FACBC) accumulates in prostate cancer cells due to over-expression of multiple amino acid transport systems. A recent Italian study suggests that anti-18F-FACBC scans may be superior to C11-choline for localization of disease in PSA recurrence. At the meeting Dr. Oluwaseum Odewole from Emory University presented results of a study comparing the accuracy of anti-18F-FACBC with the accuracy of a standard CT scan. Seventy of 86 patients (81.4%) were positive for detecting cancer with anti-F18-FACBC versus only 16 of 86 (18.6%) on the CT examinations. PSA level was also important in the detection rate for anti-18F-FACBC with the positivity rate at a PSA <1 ng/mL for anti-18F-FACBC of 38.5%, while for PSA ≥ 1 scan positivity rate was 89.0%. The results of this study appear to be fairly comparable to that of C11-Acetate and Choline, especially when the PSA is > 1 ng/mL.

Bony Matrix

Sodium Flouride (F18-NaF) is readily absorbed into the matrix of bone and has very high affinity for bone metastasis. F18-NaF PET/CT has been shown to provide higher sensitivity and specificity than technetium based planar and SPECT bone imaging for detection of osseous (bone) metastases in prostate cancer. With all of the molecular imaging probes thus far discussed, the consensus from the conference was that bony metastasis can be identified more readily with these PET imaging probes compared to conventional imaging. There was general agreement from the various presenters, however that all of these probes missed very small bony lesions which had only a very small volume of cancer cells, but these lesions were often seen on F18-NaF PET. In a separate session at the meeting, I presented the results of a direct comparison study of C11-Acetate PET to F18-NaF PET in 185 patients. F18 showed a slightly higher rate of detection of bony metastasis (41%) compared with C11-Acetate (32%). Overall however, the best detection rate came with using both C11 and F18.

Conclusion

For evaluation of the intact prostate gland as part of initial diagnosis, under active surveillance, and for targeted biopsy, multiparametric MRI is becoming the imaging study of choice. PET scans are not likely to compete with MRI in this area in the immediate future. However, they may be complimentary, especially in patients with higher risk disease to rule out the presence of local and distant metastatic disease.

With the plethora of these different types of PET scans (and particularly with
the many variations on PSMA probes), the question however remains which is the best? The following characteristics appear important: 1) a fluorine (F18) tag would be optimal as this is the most widely used cyclotron produced isotope, is readily available throughout the US, and would result in the most cost effective agent, 2) low radiation dose to the patient and to those who work with the agent, 3) rapid clearance from the background, 4) high specificity and 5) little or no urinary excretion. Unfortunately, none of the imaging probes to date meet all of the optimal characteristics. The point regarding urinary excretion is important, as high urinary excretion in the ureters and urinary bladder cause significant interference with detection of lesions in the nearby areas (i.e the prostate, prostate bed and adjacent lymph nodes). The PSMA probes have the potential to have the highest specificity, but unfortunately, all these probes to date demonstrate high urinary excretion and high background in the blood pool, which may hamper the overall usefulness of these agents. C11-Acetate and C11-Choline offer several of the desired characteristics, but the short half-life of the C11 isotope requires more costly dedicated equipment. Of these probes, F18-FACBC perhaps comes closest to having the optimal characteristics and will be of keen interest for further evaluation as a first line imaging study for detection of metastatic prostate cancer and in the evaluation of PSA recurrence.

Dr. Almeida will be speaking at the 2015 Moyad and Scholz Mid-Year Update, see page 11 for more details.

A generous donor has blessed PCRI with a $500,000.00 donation matching program that matches dollar for dollar any funds donated to our “Imaging Awareness Campaign”

1,000,000 men receive unnecessary biopsies every year when mp-MRI is less invasive and just as accurate.

Donate today & help us spread the news!

Video URL: www.goo.gl/RJCRoK

www.PCRI.org/Donate
The American College of Radiology (ACR) recently released the new guidelines for the performance and interpretation of prostate MRI with the European Society of Uroradiology (ESUR). The accompanying reporting guidelines, known as “Prostate Imaging Reporting and Data Systems” or “PI-RADS” is given the “v2” designation as the first version was released two years ago by the ESUR. Our understanding of the utility of prostate MRI has improved markedly in the interim. The guidelines are now streamlined, and in many ways simplified, while taking into account a deeper understanding of how each of the components of multi-parametric magnetic resonance imaging (mpMRI) influence the overall assessment, which is given as a “score,” from 1-5. (see table below)

These new guidelines include recommendations for the scanners used to perform mpMRI scans and the protocols utilized for the scan in addition to standardizing evaluation and reporting. This should provide more uniform reports regardless of the reporting institution. A number of medical articles have shown that using the older recommendations for performance and reporting improve the diagnostic accuracy for less experienced readers. The new recommendations should improve this further.

What does this mean for patients? It is unlikely to have an obvious impact on the experience in the scanner, or in the physician’s office or examination room, since the effects of PI-RADS would largely take place behind the scenes. The major change will be that scans performed at less experienced centers might now adhere to protocols that will make scans more universally interpretable, increasing availability of quality mpMRI scans. At sites where mpMRI is well-established, however, it is unlikely to result in a significant change, since many of these sites have already adapted reporting to their optimized scanner protocols based on correlation with clinical factors. At more experienced sites, the reporting can be refined based on correlation with pathology and outcomes, potentially improving upon the benefits achieved by standardized reporting.

The hope is that as these performance and reporting protocols are put into practice, the understanding of how well these evaluation criteria correlate with pathology and outcomes will improve beyond single-site experience. We currently do not know with certainty how well each of the overall assessment levels correlates with the likelihood of finding significant disease, as this will depend on the patient population being studied in addition to technical factors. It is straightforward to determine the performance of the standardized assessment criteria at a single center, but slight variations from site to site make generalization complex. The ACR is planning to establish a network to do just that, but it will take time to perform the analysis. In the meantime, the reporting recommendations will at least improve the performance at less experienced centers.

| PI-RADS 1 | Clinically significant cancer highly unlikely to be present |
| PI-RADS 2 | Clinically significant cancer unlikely to be present |
| PI-RADS 3 | Clinically significant cancer equivocal to be present |
| PI-RADS 4 | Clinically significant cancer likely to be present |
| PI-RADS 5 | Clinically significant cancer highly likely to be present |
Recently, the PCRI Helpline received a call from a newly diagnosed man. Having no health insurance, Mr. R’s only entry into the health care system was as a military veteran through his local VA center. A PSA test had come back elevated the year before and his doctor wanted him retested. For some reason the test got delayed, and Mr. R. had to call his urologist several times to try and reschedule. After months of delays, Mr. R. had a second PSA test that was also high, 13.8. Because he is African-American and at higher risk for prostate cancer, his doctor scheduled him for a biopsy.

Mr. R. was informed that he had prostate cancer by a message left on his answering machine, which was overwhelming and frustrating for him. He was also told to schedule an immediate appointment to see his urologist. At that appointment, Mr. R. was told he had to schedule surgery immediately, but he left with no understanding of his personal cancer characteristics. He did not know his Gleason Score or what a Gleason was. He did not know how many biopsy cores were cancerous, or the size of his prostate. And he left with no medical records.

Following his instincts, Mr. R. told his doctor he needed to understand other options first and called the PCRI Helpline. During that call, the Helpline explained that every prostate cancer is different, and it is critical to understand the characteristics of each case. We suggested he obtain copies of his medical records and gave him a short and simple list of what to ask for at his doctor’s office.

On the follow up call, the Helpline staff helped Mr. R. understand his biopsy report which showed significant amounts of Gleason Score 9, and cancer in all 12 cores. He was only age 56. We helped him understand that he would be categorized as high risk prostate cancer because of his Gleason and PSA, and it would be prudent to also get an opinion from a radiation oncologist. We helped him to look at both risk and benefit when choosing a treatment, and helped him develop questions for his physicians based on his personal situation. Even though this was overwhelming at times, Mr. R. was confident, determined, and felt glad that he trusted his instincts to not rush into surgery. He felt empowered that he now had a basic but clear understanding of his Gleason and PSA.

The PCRI Helpline also helped to connect Mr. R. with an UsTOO support group in his city, where some of the men were familiar with the VA system, and local resources. This contact might help give him ongoing support through whatever treatment decision he makes. He now understands that every prostate cancer is different, and most importantly, how his case was different. His instincts to follow up, ask questions, and not rush into a treatment were validated by what he learned, and his instincts served him well.
The PCRI was founded in 1996 to address the prevailing lack of understandable information available to the prostate cancer patient. Back then we addressed this problem by starting a helpline, this newsletter, and the first website aimed at patient education and empowerment. At that time, information on the topic was sparse and while there were alternative treatments for PCa, few people knew about them. The landscape has dramatically shifted. Now with an overflow of available information, it is difficult for patients to judge the quality or bias of the vast amount of available information. Times are changing, PCRI has evolved to meet these needs.

Our strategy to help patients navigate this confusing terrain by offering programs that help them understand their personal case. We inform patients of the specific obstacles they are likely to run into while on their journey, and explain the best way of circumventing them while getting the best outcome. Knowledge of one’s personal case leads to the information they need, avoiding the confusion that comes with the information they do NOT need.

Through our programs, we take a unique approach towards patient empowerment. Our goal is to assist you with your research, helping you weigh the risks and benefits of the decisions that you and your doctor make together. Our experienced Helpline staff can answer questions, define terms, and help you decipher your medical records. Our conference puts you in touch with leading doctors and researchers so you are aware of cutting edge care and management techniques. Our website and this newsletter are a resource not just for information but tools that enable you to understand your own personal case.

We help you research your options and empower you to converse with your medical team so you can decide what is right for you, after you have sifted through the risks and benefits of each option.

Our updated logo, graphics, and slogan are a reflection of our evolution to help meet the needs of prostate cancer patients, and our mission to help them achieve the best care and outcome possible through effective shared decision making. □
Daniel Margolis, MD, Assistant Professor of Radiology, University of California Los Angeles
Dr. Margolis is a world leading expert in the use of MRI for prostate cancer and is interested in its use for characterization of cancer and efficacy of treatment.

Topic: MP-MRI for Newly Diagnosed Prostate Cancer

Fabio Almeida, MD, Medical Director, Arizona Molecular Imaging Center
Dr. Almeida is one of the pioneers in the development and implementation of cross modality fusion for cancer imaging (SPECT, PET, CT and MRI).

Topic: PET Scans for Relapsed Prostate Cancer

Mark Moyad, MD, Jenkins/Pokempner Director of Complementary & Alternative Medicine, University of Michigan Medical Center
Dr. Moyad is arguably the world’s leading medical expert on dietary supplements and nutrition.

Topic: Diet and Supplements for Prostate Cancer

Mark Scholz, MD, Medical Director, Prostate Oncology Specialists
Dr. Scholz specializes in treating prostate cancer and is the author of the book “Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment or Loss of Potency.”

Topic: Testosterone for Men with Prostate Cancer

Register today at: WWW.PCRI.ORG

REGISTRATION IS $20
SPACE IS LIMITED

Featuring:

- Presentations from World Renowned Physicians
- Information on Modern Imaging for Prostate Cancer
- Information About the Latest Research in Diet and Supplements for Men
- A Lecture About Testosterone and Estrogen for Men and Women
- Exhibits Featuring Companies Leading the Fight Against Prostate Cancer
- Q&A Session with Drs. Moyad & Scholz

Where: Los Angeles Airport Marriott
When: April 11, 2015
1:00-4:00 PM
PSYCHOLOGICAL SIDE EFFECTS OF HORMONE THERAPY

About half of all men treated for prostate cancer will be prescribed hormone therapy—more accurately known as Androgen Deprivation Therapy (ADT)—at some time along their cancer journey. ADT is often started prior to radiotherapy to improve the efficiency of that treatment. When used that way, it is called neo-adjuvant therapy. ADT is also used as a second line therapy when patients experience a continuing rise in PSA or have other evidence of residual disease after either a radical prostatectomy or some form of radiotherapy undertaken with the intent to cure the disease. In those situations ADT is considered adjuvant therapy. Lastly, ADT is used as a systemic therapy to treat the disease when it has spread beyond the prostate gland.

A DT deprives the body of the main androgen, testosterone, the key hormone that normally promotes prostate cell growth. Although ADT is not considered curative, for many patients it can hold prostate cancer in check for years, sometimes for decades. In the early stage of metastatic disease, ADT can also cause some painful metastases to regress, improving patients’ quality of life.

ADT obviously benefits many patients. The downside is that ADT is now known to cause an array of side effects and some of those are substantial. Long-term use of ADT increases the risk of osteoporosis, bone fracture, anemia, weight gained as fat with a concomitant loss of muscle mass (that combination is called sarcopenic obesity), and possibly cardiovascular disease, kidney disease and diabetes. Much has been written about strategies for reducing the more serious metabolic and musculoskeletal side effects of ADT. Less attention has been given to the psychological impact of ADT, which I am focusing on here.

Let’s start with the normal roles of testosterone in the body. Testosterone (along with its more potent derivative, dihydrotestosterone) gives men the multitude of features that define males as men and distinguishes them from most females. This includes their more muscular bodies, their facial hair, and their propensity to go bald in middle age. Most notably, testosterone gives men their sex drive, which is diminished in most men on ADT.
But psychologically testosterone does more than that. Testosterone has been described as a “social hormone” [1] for it not only regulates men’s desire for sex, but also their propensity to compete with other individuals; i.e., in popular lingo it gives men their “machismo.” Many studies report men feeling less energetic, less motivated, and to some degree less macho while on ADT. In sum, ADT impacts on how men feel about themselves and interact with others. This is revealed in many ways, and is discussed further below.

**Depression**

Although low testosterone is not necessarily a primal cause of depression, testosterone levels decline naturally with age, and low testosterone has been associated with depression in some middle-age and older men, who are not cancer patients. In cancer patients, depression may be linked to some extent with anxiety associated with disease progression. Putting men on ADT doesn’t make that situation any better. DiBlasio et al. [2] reported “a three-fold increase…between rates of pre-ADT psychiatric illness and development of de novo illness” after starting on ADT. More recently Lee et al. [3] confirmed in a controlled study that ADT is most notably associated with an increased risk of depression. Those authors make a plea for clinicians to both screen patients on ADT for depression and intervene when they find it.

**Cognition**

There have been several studies suggesting that ADT also impacts cognitive functions. Cognitive functions are those mental processes involved in how we perceive, think, reason, and remember. Patients anecdotally report memory problems on ADT, but some of that may be due to normal aging. Back in 2008, Nelson et al. [4] however reported that between 47% and 69% of men on ADT experience some impairment in at least one cognitive domain. They concluded that ADT “is linked to subtle, but significant cognitive declines in men with prostate cancer” and felt that clinicians should “inform and monitor patients for this possible side effect of treatment.”

Recently McGinty et al. [5] revisited this topic with a meta-analysis of studies completed to date on ADT and cognition. They flagged visuomotor tasks as the domain where patients on ADT were most likely to experience cognitive decline. In real life, this can manifest itself in problems with finding papers on a messy desk, car keys left somewhere about the house, and even locating the car itself in a large parking lot. McGinty et al. reinforce Nelson et al.’s conclusion, asserting that “knowledge of the cognitive effects of ADT may help patients and [healthcare] providers better understand the impact of ADT on quality of life.”

**Men & Emotions**

Changes in emotionality have been repeatedly reported for androgen-deprived prostate cancer patients (as well as male-to-female transsexuals, who similarly go on androgen-depriving treatments), but these have not been precisely characterized and may be manifested in different ways by different men. In general terms, they range from men becoming more sentimental to more irritable [6].

The most conspicuous change that has been reported is an increase in tearfulness. In our society women may cry, but in the cultural stereotype for the western world “real men” don’t cry. Increased tearfulness can thus be embarrassing to men on ADT.

How men see this increased emotional ability, and whether they accept it or not, may have a great impact on how well they adapt to ADT in general. It is not inconsequential that for half of our species, crying is seen as empathetic and not necessarily a negative personality trait. I have met a fair number of patients on ADT, who announced that they now share tissues with their partner when they go to a dramatic movie…and feel closer to their partner as a consequence. However such open acceptance of the changes brought on by ADT is not always easy. Some men, who are not comfortable with the changes they are experiencing, feel ashamed or out of control at being seen by others as acting, or reacting, differently than they did before ADT. In contrast to the patients who acknowledge and accept emo-
tional change, they strive to hide it and perhaps hope that it will go away—or at least go unnoticed. They then get distressed and even angry if it is recognized and commented on by someone else.

**Impact on The Partners**

The “someone else” is often the patient’s partner, who sees ADT-induced changes in their partner’s personality before he sees them in himself. This can lead to conflict between patients and partners if they have different coping strategies. Often women find it beneficial to talk out problems, whereas men often resort to denial as a defensive mechanism, particularly when facing problems they cannot easily solve. That can lead to frustration and then depression in the patient’s partner, who may feel rebuffed and rejected, when the patient wants to neither acknowledge nor discuss how different he feels on ADT. [Various research groups have described versions of this conflict when heterosexual couples are challenged by ADT; the impact of ADT on same sex couples has yet to be investigated.]

In sum, ADT can negatively impact on a man’s interactions with the person he is normally closest to, and this can have repercussions on that person’s health.

In general, the psychological distress associated with cancer is greater on females then on males whether they are the patient or the partner [7]. This has recently been documented for a variety of cancers, including prostate cancer, where the female partners show persistently higher levels of anxiety than the male patients [8]. In fact, over 20 years ago Kornblith et al. [9] reported greater psychological distress in the partners than the patients on ADT.

To put this in slightly glib terms, ADT can cause a “communicable iatrogenic psychiatric disorder”. In other words he is medically emasculated, not acting quite like he used to, and she is now depressed. As a part of informed consent, when starting patients on ADT, one might suppose that patients and partners would be informed of this possibility as part of routine clinical practice. But that doesn’t always happen. In defense of the healthcare establishment, the depth and breath of this problem has become much worse over the last 20 years as more men are living much longer on ADT. And out of fairness to uro-oncologists, the care they provide should be focused on the patient. After all, keeping him from dying of prostate cancer is a major step in the right direction for reducing distress in his partner. However there is reason for healthcare providers to be particularly concerned about the psychological burden on the partners of prostate cancer patients since the distress in the partners correlates with the distress in patients. In fact Kim et al. [10] showed that there is “evidence of partner effects, at least for women. That is, women’s distress predict[s] men’s physical health, over and above the men’s distress, …age, and cancer stage.” Seen in that light, all of us—patients, partners, and healthcare providers—should be concerned about the health and welfare of not just patients on ADT, but also their partners.

**Helping Patients & Partners Deal with The Adverse Effects of ADT**

Going one step further, I would argue that we should be concerned not just about the individuals, but about preserving their partnership as a co-supportive dyad. Too often cancer treatments can be so debilitating that they cause co-supportive partnerships to devolve into a patient/caregiver dynamic. Our job should be to help prevent that. Strong partnerships are first and foremost built on intimacy, which means sharing something with someone that one doesn’t share with others. When we are young, sex is a bonding act, an intimate act that builds partnership. But when we age—and in particular for patients on ADT whose sexual desire is depressed—maintaining intimacy and protecting partnership can be challenging.

When it comes to dealing with ADT side effects, whether they are the physiological ones affecting the cardiovascular and musculoskeletal systems, or the psychological ones affecting the patient’s mood and emotionality, there is one intervention that can help across the board. That is physical exercise. Not only can exercise protect the heart, bones, and muscles, but it can improve mood and
memory, reduce depression and fatigue, and recently it has even been shown to improve sexual function for patients on ADT [11].

To bring this back to the psychological impact of ADT on patients and its indirect impact on partners, exercising together can help maintain intimacy and thus help keep prostate cancer couples together. In that regard, I am particularly impressed with the “Exercising Together” program for prostate cancer patients developed at the Oregon Health & Science University (OHSU) in Portland, Oregon [12]. This is a partnered, strength-training program for prostate cancer couples, which essentially trains patient and partner to work as a training team, partly by being the fitness trainer for each other and partly by doing exercises in tandem. The final results of that study are soon to be submitted for publication, but preliminary analyses show that partnered exercise is helpful not just in strengthening patients’ and partners’ bodies and minds, but also strengthening their spousal bond. The Vancouver Prostate Cancer Supportive Care program where I work is now piloting a modified version of the program.

Not all prostate cancer patients have life partners, but having one and keeping one’s partnership strong and healthy is one of the most effective treatments for prostate cancer. As Aizer et al. [13] noted, the survival benefit for prostate cancer patients in having a supportive spouse (call it marriage if you will) beats any benefit of chemotherapy.

References can be found online at PCRI.org
Primary Risk Factors:

- Hormone therapy treatment
- Over age 50
- Having a thin frame/stature
- Tobacco use
- Excessive alcohol or caffeine
- Lack of exercise
- Vitamin D deficiency
- Thyroid or parathyroid problems
- Cortisone use
- Previous fracture
- Bone metastases

There are several types of bone density tests, but the most common are the DEXA Scan and the QCT. PCRI Executive Director, Dr. Mark Scholz, states that “…only QCT is accurate in men. In men, DEXA seriously underestimates the degree of osteoporosis.” However, the DEXA Scan is certainly the most commonly used scan, and easier to locate, but it is worthwhile to look for a radiology site that offers the QCT. Both tests are quick, easy, and do not require an injection.

Table 1

<table>
<thead>
<tr>
<th>Categories</th>
<th>T-Score Range</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Bone Density</td>
<td>-1 and above</td>
<td>1.0, 0, -.5</td>
</tr>
<tr>
<td>Osteopenia</td>
<td>Between -1 and -2.5</td>
<td>-1.1, -1.5, -2.4</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>-2.5 and below</td>
<td>-2.5, -3.0, -4.0</td>
</tr>
</tbody>
</table>

Many prostate cancer patients have had a bone scan as part of their original staging, or checking for recurrence. It is important not to get this confused with a bone density test – they are different. The bone scan looks for cancer, and the bone density test looks for osteoporosis.

Your Bone Density Report

PCRI recommends that you obtain and keep copies of your medical records, including the written report from your bone density test. These reports can look daunting at first, but if you learn what to look for, you can develop a basic understanding of the key important findings. In the case of a bone density report, it is primarily one score that you are looking for, the T-Score. This is the score that gives you a diagnosis, and the state of the density of your bones. (See Table 1.)

Treating Osteopenia or Osteoporosis

There are several approaches to treatment, but weight-bearing exercise or resistance exercise is foundational. Exercise in general is of great overall benefit to prostate cancer patients. Of course, this should be discussed with a professional, especially if you already have bone loss, or have been diagnosed with bone metastases. But research has shown that weight-bearing exercise not only builds muscle, but can also build bone density.

Estrogen has also been shown to play a role in bone health. Studies have shown that estrogen can help men with bone loss, hot flashes, and sometimes even fight their prostate cancer. Testosterone is converted to estrogen and that stimulates bone health. Estrogen, which is missing in men on hormone therapy, can be administered safely in the form of a low-dose skin patch. Estrogen is one way to slow the rate of bone loss.

In addition to exercise and estrogen, there are additional treatments available for prostate cancer patients who have osteoporosis, bone metastases, or both. It is important to note that all of the treatments in Table 2 recommend a dental exam before starting therapy and supplementing with and/or monitoring levels of both calcium, and vitamin D3.

In addition to the treatments listed in Table 2, there are prescription pills which are in the same class of drugs as Zometa & Reclast (bisphosphonates), which are designed to prevent and treat bone loss. They include Fosamax (alendronate), Boniva (ibandronate), and Actonel (risedronate).
How Long Should I Stay on Zometa, Xgeva, or Prolia?

Every treatment decision is a risk (side effects) vs benefit (disease response) decision. Clearly these drugs offer great benefit for many patients. If taken correctly (dental checkups, daily calcium, daily vitamin D), then the benefit can be significant.

Experts may have different opinions on how long a prostate cancer patient should stay on these treatments. But there is general agreement that it is possible to be on them for too long. The greatest benefit from these treatments probably occurs in the first year or two. There is some disagreement as to when risk of side effects begins to outweigh the benefits. This is an ongoing discussion that you should have with your medical oncologist, and your nurses. In addition, ask about retesting your bone density after you have taken steps to improve it. It is important to have a way to measure the benefit of any therapy.

Prostate cancer patients live in a world where shared decision making with one's doctors is not only important, but it is encouraged. Understanding your personal risk of osteoporosis is a great place to start. It will help you develop a basic understanding of how to access your medical records, a process you will find is very empowering. We don’t accept mental recall or verbal information for other important matters in our lives, such as our finances, our taxes, or our children’s report cards. Why do we accept it for personal medical information?

**Table 2**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Insurance Eligible Patients</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zometa (Zolendronate)</td>
<td>PC patients with bone metastases</td>
<td>IV Drip Monthly</td>
</tr>
<tr>
<td>Xgeva (Denosumab)</td>
<td>PC patients with bone metastases</td>
<td>1 Shot Monthly</td>
</tr>
<tr>
<td>Prolia (Denosumab)</td>
<td>Men with osteoporosis at high risk of fracture or pc patients on hormone therapy (no bone mets) at high risk of fracture</td>
<td>1 Shot Every 6 Months</td>
</tr>
<tr>
<td>Reclast (Zolendronate)</td>
<td>Men with osteoporosis</td>
<td>IV Drip Annually</td>
</tr>
</tbody>
</table>

How Long Should I Stay on Zometa, Xgeva, or Prolia?

Every treatment decision is a risk (side effects) vs benefit (disease response) decision. Clearly these drugs offer great benefit for many patients. If taken correctly (dental checkups, daily calcium, daily vitamin D), then the benefit can be significant.

Experts may have different opinions on how long a prostate cancer patient should stay on these treatments. But there is general agreement that it is possible to be on them for too long. The greatest benefit from these treatments probably occurs in the first year or two. There is some disagreement as to when risk of side effects begins to outweigh the benefits. This is an ongoing discussion that you should have with your medical oncologist, and your nurses. In addition, ask about retesting your bone density after you have taken steps to improve it. It is important to have a way to measure the benefit of any therapy.

Prostate cancer patients live in a world where shared decision making with one’s doctors is not only important, but it is encouraged. Understanding your personal risk of osteoporosis is a great place to start. It will help you develop a basic understanding of how to access your medical records, a process you will find is very empowering. We don’t accept mental recall or verbal information for other important matters in our lives, such as our finances, our taxes, or our children’s report cards. Why do we accept it for personal medical information?

- Osteoporosis is: A disease, seldom tested for in men, easy to test for, easy to treat, and the leading cause of fracture in men of advanced age
- A bone density test is NOT the same as a bone scan
- Hormone therapy can cause bone loss
- Patients should get a dental checkup before starting Zometa, Reclast, Xgeva, or Prolia
- It is recommended that patients take calcium & vitamin D3 while on Reclast, Zometa, Xgeva, or Prolia
- Calcium & vitamin D levels can be measured with a blood test
- Patients should talk to their medical oncologist about how long they should stay on Zometa, Reclast, Prolia, or Xgeva
The Prostate Cancer Research Institute’s annual conference is the leading conference for prostate cancer education and support. The conference provides a weekend of educational sessions on treatment options, both new and of landmark importance, and addresses lifestyle and quality of life issues. Information is presented by world-renowned physicians and researchers. The keynote sessions are moderated by Dr. Mark Moyad, a leader in the fight against prostate cancer, who makes it personal and relevant to the patients in the audience. In addition, there are opportunities throughout the 3-day event to participate in Q&A sessions with the faculty, hear in-depth presentations about particular treatment options, attend support groups with other patients, and meet with various organizations and companies who provide services and products for prostate cancer patients.

Mark Moyad, MD
Jenkins/Pokempner Director of Complementary & Alternative Medicine
University of Michigan Medical Center

Mark Scholz, MD
Medical Director
Prostate Oncology Specialists & Executive Director
Prostate Cancer Research Institute

Specialists & Topics

*Speakers & Topics

Tomasz Beer, MD
Oregon Health and Science University
Zyntiga and Xtandi

Charles Drake, MD
Johns Hopkins School of Medicine
Immune Therapy

Peter Grimm, DO
Prostate Cancer Center of Seattle
Seed Implant Radiation

Mark Moyad, MD
University of Michigan Medical Center
Diet and Supplements

John Mullhall, MD
Memorial Sloan-Kettering
Sexual Side Effects

William Oh, MD
Mount Sinai School of Medicine
Hormone Resistance

Travel

The conference is held at the Los Angeles Airport Marriott. A special room rate of $105/night is available until August 20th, 2015 by calling the Marriott directly at 310.641.5700 or by visiting www.PCRI.org for the online booking link.

Discounted airplane booking with DELTA is available via www.delta.com. When booking online, select Book A Trip, click on Advanced Search and use the meeting code NMKZ8. Discount car rental through AVIS using discount code #D374541. There is a complimentary shuttle from LAX terminals to the Marriott. A reduced self-parking rate of $12/day is available for those who are driving to the conference.
For one weekend out of every year, PCRI holds a conference where patients gather together and collectively learn about the latest in prostate cancer care and lifestyle as well as treatments of landmark importance. The conference brings hundreds of patients, caregivers, support group leaders, and physicians together for a long weekend of lectures and interactive sessions.

Patients will interact closely with the world’s most knowledgeable physicians as well as recognized academic researchers, who have extensive experience or specialty in prostate cancer care and are from top notch medical institutions.

Our engaging faculty communicates this information in a way that the attendees can comprehend and apply to their own case, so they can take action. Over the course of the weekend, attendees often collaborate to help process and understand the wealth of information that is presented.

**Roundtable discussion:** A panel where conference faculty discuss their medical opinions on real clinical cases.

**Q&A with the Speakers:** Conference attendees may ask faculty specific questions in a more intimate setting.

**Ask the Experts:** 90-minute interactive sessions that focus on topics such as Medical Oncology, Urology, Radiation Oncology, Immunotherapy, nutrition, a prostate-friendly lifestyle and much more.

**Support Groups:** With the help of PCRI’s partners and professional facilitators, support group meetings are available to patients and their significant others.

**Exhibit Hall:** Ballroom where attendees view display booths and materials, interacting with representatives from exhibiting companies and partnering organizations.

Learn more at: www.PCRI.org